All In Biotech

Drug Trial Radar · NCT05391022

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Jul 20, 2021

Primary completion

Mar 8, 2023

Study completion Feb 29, 2024

Sponsor

Lead sponsor
Constellation PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

Conditions

  • Advanced Malignancies
  • Solid Tumor
  • Hematological Malignancy

Interventions

  • PelabresibDrug

    Pelabresib monohydrate tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Run-In Food Effect Period: Area under the concentration time curve (AUC) based on pelabresib concentrations in plasma measured using validated plasma assayTime frame: 21 days
  2. Run-In Food Effect Period: maximal plasma concentration (Cmax) based on pelabresib concentrations in plasma measured using validated plasma assayTime frame: 21 days
  3. Run-In Food Effect Period: Time to maximal plasma concentration (Tmax) based on pelabresib concentrations in plasma measured using validated plasma assayTime frame: 21 days
  4. Continuous Treatment Period: Changes in QT and QTc intervalsTime frame: 12 months

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Gettysburg Cancer Center

    Gettysburg, Pennsylvania

  • Start Mountain Region

    West Valley City, Utah

  • Hight Technology Hospital Medcenter

    Batumi, Georgia

  • K. Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • Simon Khechinashvili University Hospital

    Tbilisi, Georgia

  • Barcelona HM Nou Delfos

    Barcelona, Spain

  • Madrid - FJD

    Madrid, Spain

  • START CIOCC Hospital HM Sanchinarro

    Madrid, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.